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About 60% of patients with decompensated disease have
oesophageal varices. One third of these patients will experi-
ence variceal bleed. Each bleeding episode compromises the
decompensated state and is associated with a 20% to 30%
mortality. Bleeding from ectopic varices is rare but is gener-
ally massive and life threatening. The ﬁrst two articles, “Clin-
icopathological features and treatment of ectopic varices with
portal hypertension”a n d“ Application of endoscopy in improv-
ing survival of cirrhotic patients with acute variceal hem-
orrhage” discuss the management of variceal bleeding in cir-
rhotic patients. “Improved survival with the patients with va-
ricealbleed” is a review article on how new treatment modal-
ities have improved the outlook of patients with bleeding
oesophageal varices.
The hepatorenal syndrome (HRS) signiﬁes advanced
liver failure and is a bad prognostic factor in patients with
decompensated cirrhosis. Management of this condition is
discussed in “Management of renal failure and ascites in pa-
tients with cirrhosis”. One of the features of decompensated
liverdiseaseistheoccurrenceofrecurrentorresistantascites.
Transjugular intrahepatic portosystemic shunt (TIPS) is an
eﬀectivetherapyforrefractoryascitesandHRSattheexpense
of hepatic encephalopathy and may oﬀer an eﬀective bridge
to liver transplantation, by improving short and medium
termsurvivals,asdiscussedin“Role ofTIPSinimproving sur-
vival of patients with decompensated liver disease”.
Bacterialinfectionisresponsibleforuptoaquarterofthe
deaths of patients with decompensated liver disease. “Pre-
vention and management of bacterial infections in cirrhosis”
discuss the high index of suspicion that is needed to pre-
vent bacterial infections in patients with decompensated
cirrhosis. These patients are immunologically compromised,
and prophylactic antibiotics can prevent fatal septicemia
and HRS in those with gastrointestinal bleeding. Current
thoughts on how to deal with the neuropsychiatric compli-
cation of cirrhosis are discussed in “Management of hepatic
encephalopathy”. Cardiomyopathy, hepatopulmonary syn-
drome, portopulmonary hypertension and right-sided hy-
drothorax complications that are often overlooked in pa-
tients with decompensated liver disease are discussed in
“Management of cardiopulmonary complications of cirrhosis”.
Decompensated liver cirrhosis has been traditionally consid-
ered as a prototype of hemorrhagic coagulopathy, and rou-
tinely performed coagulation proﬁle is abnormal in the ma-
jority of these patients. In “Management of coagulopathy in
patients with decompensated liver disease”, the authors dis-
cussed recent thoughts on coagulation in end-stage liver
disease. The related article entitled “Determination of
ADAMTS13 and its clinical signiﬁcance for ADAMTS13 sup-
plementation therapy to improve the survival of patients with
decompensated liver cirrhosis” reviews the role of the deﬁ-
ciency of the metalloproteinase ADAMTS13 in end-stage
liver cirrhosis in inducing platelet clumping or thrombi and
how the resulting sinusoidal microcirculatory disturbances
causes further liver damage and is closely related to further
deterioration of liver function, hepatic encephalopathy, he-
patorenal syndrome, and intractable ascites in advanced
liver cirrhosis. Fresh frozen plasma (FFP) is a source of
ADAMTS13.
Livercirrhosisisthecommonendstageofpersistentliver
injury. In the Asia Paciﬁc region, these injuries commonly
result from chronic hepatitis B and C infections as well as2 International Journal of Hepatology
alcohol. The following two articles, “Treatment of hepatitis
B in decompensated liver cirrhosis and treatment of decom-
pensated alcoholic liver disease” address the management of
hepatitis B and alcoholic liver disease in end stage liver dis-
ease. Pharmacotherapy in patients with decompensated liver
disease is not without complications and side eﬀects and
might compromise the decompensated state. The article en-
titled“Prescribingmedicationsinpatientswithdecompensated
liver cirrhosis” addresses the above conundrum. A common
complication of liver cirrhosis is liver cancer, and treatment
of this condition is challenging in patients with liver decom-
pensation to say the least. The paper entitled “Screening for
hepatocellular carcinoma” discusses early detection of liver
cancer in these patients so that appropriate management can
be arranged. Finally, liver transplantation for end-stage liver
failure is discussed in “Indications and contraindications for
liver transplantation”.
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